Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Last trade$6.97
Day change-$0.40 (-5.43%)
Day range$6.92 – $7.74
Volume720,905
Market cap$426M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$426.16M
Price / earnings
—
Price / book
0.98×
Price / sales
7,222.99×
EV / sales
6,121.49×
EV / EBITDA
-3.78×
Profitability
Earnings per share
-$1.53
Return on assets
-18.41%
Return on equity
-20.31%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
16.63×
Quick ratio
16.63×
Cash ratio
2.7×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AVTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$59K
$0
$0
$0
$192K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$87K
Gross profit
$0
$0
$0
$59K
$0
$0
$0
$105K
Selling, general and administrative
$8.35M
$8.1M
$6.85M
$6.53M
$5.58M
$5.24M
$5.55M
$5.23M
Research and development
$15.05M
$23.42M
$14.05M
$13.27M
$13.62M
$14.07M
$9.12M
$8.18M
Total operating expenses
$23.4M
$31.52M
$20.9M
$19.8M
$19.2M
$19.32M
$14.67M
$13.42M
Operating income
-$23.4M
-$31.52M
-$20.9M
-$19.74M
-$19.2M
-$19.32M
-$14.67M
-$13.31M
Interest expense
$4.25M
$2.76M
$803K
$0
$1.11M
$1.1M
$1.15M
$0
Income before taxes
-$18.94M
-$36.34M
-$19.62M
-$13.59M
-$30.61M
-$20.75M
-$13.14M
-$35.23M
Income taxes
$7K
$18K
$12K
$130K
$11K
$16K
$8K
$114K
Net income
-$18.95M
-$36.36M
-$19.63M
-$13.72M
-$30.63M
-$20.77M
-$13.15M
-$35.34M
Net income attributable to common shareholders
-$18.95M
-$36.36M
-$19.63M
-$13.72M
-$30.63M
-$20.77M
-$13.15M
-$35.16M
EBITDA
-$23.38M
-$31.5M
-$20.88M
-$19.73M
-$19.14M
-$19.18M
-$14.53M
-$13.24M
Basic earnings per share
-$0.34
-$0.83
-$0.98
-$0.75
-$2.19
-$1.92
-$1.25
-$3.43
Diluted earnings per share
-$0.34
-$0.83
-$0.98
-$0.75
-$2.19
-$1.92
-$1.25
-$3.29
Recent news
Company coverage with links to the original publishers.
Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β pathway therapeutics, announced its inclusion in the Russell 2000 and Russell 3000 indexes effective June 26, 2026. The company's lead asset abdakibart, an anti-IL-1β monoclonal antibody, recently reported positive Phase 2 data in hidradenitis suppurativa, with plans to advance next-generation candidate AVTX-010.
Avalo Therapeutics priced an underwritten public offering of 19.73 million shares at $17.75 per share and 1.4 million pre-funded warrants, expected to raise approximately $375 million in gross proceeds. The company plans to use the funds to advance clinical development of its lead asset abdakibart, including Phase 3 topline data release, following positive Phase 2 results in hidradenitis suppurativa. The offering is expected to close on May 7, 2026.
Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, announced that management will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. The company's lead asset, AVTX-009, is currently in Phase 2 clinical trials for hidradenitis suppurativa.
A comprehensive analysis reveals a robust pipeline for hidradenitis suppurativa treatment, with 24+ companies developing 26+ therapies, focusing on innovative biologic and targeted approaches like IL-17 and JAK inhibitors to address significant unmet clinical needs.
Merus NV shares jumped 38.2% in pre-market trading after Genmab announced plans to acquire the company for $8 billion in an all-cash deal, adding breakthrough therapy Petosemtamab to its late-stage pipeline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.